A Study to Evaluate the Efficacy and Safety of AD-224

Status:
RECRUITING

Trial end date:
2025-07-01

Target enrollment:

Participant gender:

The purpose of this study is to evaluate the efficacy and safety of AD-224

PHASE3

Addpharma Inc.